Published in Hum Immunol on April 12, 2012
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proc Natl Acad Sci U S A (2014) 1.11
Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96
The intestinal microbiota: its role in health and disease. Eur J Pediatr (2015) 0.88
Toll-like receptor 10-1-6 gene cluster polymorphisms are not associated with benign prostatic hyperplasia in korean population. Int Neurourol J (2014) 0.85
NOD1, RIP2 and Caspase12 are potentially novel biomarkers for oral squamous cell carcinoma development and progression. Int J Clin Exp Pathol (2014) 0.81
The associations between immunity-related genes and breast cancer prognosis in Korean women. PLoS One (2014) 0.81
Tumor-associated and disease-associated autoantibody repertoires in healthy colostrum and maternal and newborn cord sera. J Immunol (2015) 0.76
Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response. Bladder Cancer (2016) 0.76
Impacts of CA9 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan. PLoS One (2013) 0.75
Association detection between genetic variants in the microRNA binding sites of toll-like receptors signaling pathway genes and bladder cancer susceptibility. Int J Clin Exp Pathol (2014) 0.75
Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget (2017) 0.75
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol (2003) 1.87
Expanded cells in monoclonal TCR-alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood (2008) 1.61
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol (2002) 1.39
The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother (2004) 1.31
MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol (2007) 1.24
Analysis of HLA-E expression in human tumors. Immunogenetics (2003) 1.23
Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol (2007) 1.22
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer (2011) 1.19
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother (2012) 1.15
Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother (2004) 1.15
High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol (2007) 1.08
A new extract of the plant Calendula officinalis produces a dual in vitro effect: cytotoxic anti-tumor activity and lymphocyte activation. BMC Cancer (2006) 1.08
Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol (2008) 1.04
Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica (2004) 1.04
Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics (2008) 1.03
Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics (2010) 1.03
Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother (2002) 1.03
Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer (2008) 0.99
Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer (2003) 0.97
MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis (2012) 0.95
The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics (2012) 0.95
Monoclonal TCR-Vbeta13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. Blood (2007) 0.95
IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res (2008) 0.94
Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother (2005) 0.91
Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother (2008) 0.91
Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer (2005) 0.91
MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer (2003) 0.90
The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells. J Pathol (2012) 0.90
HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol Immunother (2009) 0.90
Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother (2002) 0.90
HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother (2006) 0.89
Association of a functional polymorphism of PTPN22 encoding a lymphoid protein phosphatase in bilateral Meniere's disease. Laryngoscope (2010) 0.89
VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Hum Immunol (2012) 0.88
The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer (2008) 0.88
Study of six X-linked tetranucleotide microsatellites: population data from five Spanish regions. Int J Legal Med (2005) 0.88
HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One (2013) 0.87
T lymphocytes restrain spontaneous metastases in permanent dormancy. Cancer Res (2014) 0.87
High frequency of HLA-B44 allelic losses in human solid tumors. Hum Immunol (2003) 0.87
Analysis of HLA-ABC locus-specific transcription in normal tissues. Immunogenetics (2010) 0.86
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer (2013) 0.86
Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT. Int J Cancer (2014) 0.85
Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics (2004) 0.85
Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer (2007) 0.85
Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer (2011) 0.85
Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother (2007) 0.85
Immunotherapy eradicates metastases with reversible defects in MHC class I expression. Cancer Immunol Immunother (2011) 0.85
Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. Liver Int (2013) 0.84
Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Semin Cancer Biol (2002) 0.84
LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas. Immunogenetics (2006) 0.84
Polymorphisms of CD16A and CD32 Fcγ receptors and circulating immune complexes in Ménière's disease: a case-control study. BMC Med Genet (2011) 0.83
Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy. Cancer Immunol Immunother (2006) 0.83
Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunol Immunother (2009) 0.83
A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Hum Immunol (2008) 0.82
Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. Int J Cancer (2011) 0.82
Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line. Cancer Immunol Immunother (2002) 0.82
Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Hum Immunol (2010) 0.82
Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest (2014) 0.81
Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells. Hum Immunol (2009) 0.81
Polymorphisms in DNA-repair genes in a cohort of prostate cancer patients from different areas in Spain: heterogeneity between populations as a confounding factor in association studies. PLoS One (2013) 0.81
A transcriptome-proteome integrated network identifies endoplasmic reticulum thiol oxidoreductase (ERp57) as a hub that mediates bone metastasis. Mol Cell Proteomics (2013) 0.81
Late pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: a case report. J Med Case Rep (2008) 0.81
Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape. Cancer Immunol Immunother (2011) 0.81
International conference: progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain. Cancer Immunol Immunother (2007) 0.81
Acute myeloid leukaemia of donor cell origin developing 17 years after allogenic hematopoietic cell transplantation for acute promyelocytic leukaemia. Int J Biomed Sci (2012) 0.81